Subscribe: Nature Reviews Cardiology - Issue - science feeds
Preview: Nature Reviews Cardiology - Issue - science feeds

Nature Reviews Cardiology - Issue - science feeds

Nature Reviews Cardiology provides physicians and academics with authoritative and topical discussions of key developments in the field.


Shared decision-making in HCM


Shared decision-making (SDM) between physicians and patients is a necessary element of care in hypertrophic cardiomyopathy (HCM), particularly for decisions concerning prophylactic implantable defibrillators to prevent sudden death; however, SDM has much less relevance in making eligibility versus disqualification decisions for competitive athletes with HCM.

Risk factors: Linking stress to arterial inflammation and vascular events


“Chronic stress could be treated as an important risk factor for cardiovascular disease, one that is routinely screened for and effectively managed, like other major cardiovascular disease risk factors.” This prediction by Ahmed Tawakol and colleagues is made following a new study into the relationship

Arrhythmias: Optogenetic control of cardiac rhythm


Optogenetics — a biological technique that uses light to control cell behaviour — can terminate ventricular arrhythmias in rats, as shown in a proof-of-concept study. The researchers injected rats with cardiotropic adeno-associated virus vectors, which encoded the red-activatable variant of the light-gated depolarizing ion channel,

Heart failure: Recombinant neuregulin for HF treatment


The safety and tolerability of cimaglermin-α, an isoform of membrane-bound pro-neuregulin 1 (also known as glial growth factor), was evaluated in a first-in-human, phase I, randomized, placebo-controlled trial in patients with left ventricular systolic dysfunction and heart failure (HF). The investigators observed no discontinuation of

Cell therapy: Autologous cardiac stem cells for congenital HF


Treatment with cardiosphere-derived cells (CDCs) improves ventricular function in children with single ventricle physiology, according to the findings of the phase II, randomized, controlled PERSEUS study. A total of 41 patients with single ventricle physiology undergoing second-stage or third-stage palliation were randomly assigned to receive

Acute coronary syndromes: Microbial-dependent TMAO as a prognostic marker in ACS


Trimethylamine N-oxide (TMAO), a metabolite generated in the body from a waste product of gut microbes, has been associated with the risk of cardiovascular events in individuals with stable cardiovascular disease, and was shown to modulate platelet reactivity and thrombosis potential in animal models.

Diabetes: Diabetes-induced microvascular destabilization


Diabetes mellitus can reduce microvascular density and impair microvascular growth in the heart. This finding comes from a study that utilized human myocardial tissue from patients with end-stage heart failure, and a transgenic diabetic pig model to assess the effect of microvascular destabilization on function

Device therapy: A robotic heart sleeve to keep the beat


The field of implantable robotic devices is being transformed by a new wave of biomimetic robots constructed with materials with properties matching biological tissues and designed to mimic the motions of human tissues. The benefits of biologically inspired designs were first shown with extracorporeal robots.

Venous thromboembolism: Thromboprophylaxis with statins


Use of a statin, particularly rosuvastatin, is associated with a reduced risk of venous thromboembolism (VTE), according to the results of a systematic review and meta-analyses published in Lancet Haematology.The researchers identified 36 eligible studies: 13 cohort studies (n = 3,148,259

Vascular disease: Cell therapy lowers PAD amputation risk


Critical limb ischaemia (CLI) is a potentially fatal complication of peripheral artery disease (PAD). A meta-analysis of studies that evaluated the safety and efficacy of autologous cell therapy for intractable CLI/PAD now reports that cell therapy reduces the risk of amputation and improves wound healing.

Cardiac resuscitation: Hypothermia or normothermia?


Therapeutic hypothermia (controlled cooling of core body temperature) does not improve survival and functional outcome of children who experience in-hospital cardiac arrest as compared with therapeutic normothermia, according to the findings of a multicentre, randomized trial now published in The New England Journal of Medicine

Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia


The ACCORDION trial, an extension of the ACCORD trial, confirms earlier findings showing that addition of fenofibrate to background statin therapy does not reduce cardiovascular events. However, cardiovascular events are reduced in patients with dyslipidaemia. Future trials with fibrates should restrict inclusion to patients with dyslipidaemia that persists despite statin therapy.

Inflammatory processes in cardiovascular disease: a route to targeted therapies


Inflammatory processes are firmly established as central to the development and complications of cardiovascular diseases. Elevated levels of inflammatory markers have been shown to be predictive of future cardiovascular events. The specific targeting of these processes in experimental models has been shown to attenuate myocardial

Depression and coronary heart disease


Depression is a highly prevalent risk factor for incident coronary heart disease (CHD) and for cardiovascular morbidity and mortality in patients with established CHD. Several biological and behavioural mechanisms have been hypothesized to underlie the relationship between depression and CHD, but none has been shown

Peripheral artery disease: epidemiology and global perspectives


Global populations are undergoing a major epidemiological transition in which the burden of atherosclerotic cardiovascular diseases is shifting rapidly from high-income to low-income and middle-income countries (LMICs). Peripheral artery disease (PAD) is no exception, so that greater focus is now required on the prevention and

Long-term neprilysin inhibition — implications for ARNIs


Neprilysin has a major role in both the generation and degradation of bioactive peptides. LCZ696 (valsartan/sacubitril, Entresto), the first of the new ARNI (dual-acting angiotensin-receptor–neprilysin inhibitor) drug class, contains equimolar amounts of valsartan, an angiotensin-receptor blocker, and sacubitril, a prodrug for the neprilysin inhibitor LBQ657.